77 related articles for article (PubMed ID: 18225539)
1. STAT-1 expression in human glioblastoma and peritumoral tissue.
Haybaeck J; Obrist P; Schindler CU; Spizzo G; Doppler W
Anticancer Res; 2007; 27(6B):3829-35. PubMed ID: 18225539
[TBL] [Abstract][Full Text] [Related]
2. Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas.
Gunal A; Onguru O; Safali M; Beyzadeoglu M
Neuropathology; 2008 Aug; 28(4):382-6. PubMed ID: 18298442
[TBL] [Abstract][Full Text] [Related]
3. Experimental model and immunohistochemical analyses of U87 human glioblastoma cell xenografts in immunosuppressed rat brains.
Strojnik T; Kavalar R; Lah TT
Anticancer Res; 2006; 26(4B):2887-900. PubMed ID: 16886610
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD 73 (ecto-5'-nucleotidase) in 165 glioblastomas by immunohistochemistry and electronmicroscopic histochemistry.
Ludwig HC; Rausch S; Schallock K; Markakis E
Anticancer Res; 1999; 19(3A):1747-52. PubMed ID: 10470109
[TBL] [Abstract][Full Text] [Related]
5. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans.
Schley M; Ständer S; Kerner J; Vajkoczy P; Schüpfer G; Dusch M; Schmelz M; Konrad C
Brain Res Bull; 2009 Jun; 79(5):333-7. PubMed ID: 19480992
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme.
Chang CY; Li MC; Liao SL; Huang YL; Shen CC; Pan HC
J Clin Neurosci; 2005 Nov; 12(8):930-3. PubMed ID: 16326273
[TBL] [Abstract][Full Text] [Related]
7. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue.
Lama G; Mangiola A; Anile C; Sabatino G; De Bonis P; Lauriola L; Giannitelli C; La Torre G; Jhanwar-Uniyal M; Sica G; Maira G
Int J Oncol; 2007 Jun; 30(6):1333-42. PubMed ID: 17487353
[TBL] [Abstract][Full Text] [Related]
8. Activation of the signal transducer and activator of transcription-1 in diffuse proliferative lupus nephritis.
Martinez-Lostao L; Ordi-Ros J; Balada E; Segarra-Medrano A; Majó-Masferrer J; Labrador-Horrillo M; Vilardell-Tarrés M
Lupus; 2007; 16(7):483-8. PubMed ID: 17670846
[TBL] [Abstract][Full Text] [Related]
9. Tissue plasminogen activator expression in meningiomas and glioblastomas.
Goh KY; Poon WS; Chan DT; Ip CP
Clin Neurol Neurosurg; 2005 Jun; 107(4):296-300. PubMed ID: 15885387
[TBL] [Abstract][Full Text] [Related]
10. Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas.
Anderson RC; Anderson DE; Elder JB; Brown MD; Mandigo CE; Parsa AT; Goodman RR; McKhann GM; Sisti MB; Bruce JN
Neurosurgery; 2007 Jun; 60(6):1129-36; discussion 1136. PubMed ID: 17538388
[TBL] [Abstract][Full Text] [Related]
11. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours.
Fael Al-Mayhani TM; Ball SL; Zhao JW; Fawcett J; Ichimura K; Collins PV; Watts C
J Neurosci Methods; 2009 Jan; 176(2):192-9. PubMed ID: 19215724
[TBL] [Abstract][Full Text] [Related]
12. Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins.
Ishihara H; Kubota H; Lindberg RL; Leppert D; Gloor SM; Errede M; Virgintino D; Fontana A; Yonekawa Y; Frei K
J Neuropathol Exp Neurol; 2008 May; 67(5):435-48. PubMed ID: 18431253
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas.
Hagemann C; Anacker J; Gerngras S; Kühnel S; Said HM; Patel R; Kämmerer U; Vordermark D; Roosen K; Vince GH
Oncol Rep; 2008 Aug; 20(2):301-8. PubMed ID: 18636190
[TBL] [Abstract][Full Text] [Related]
14. Cytokine signalling in the beta-cell: a dual role for IFNgamma.
Gysemans C; Callewaert H; Overbergh L; Mathieu C
Biochem Soc Trans; 2008 Jun; 36(Pt 3):328-33. PubMed ID: 18481951
[TBL] [Abstract][Full Text] [Related]
15. CD98 immunoreactivity in multinucleated giant cells of glioblastomas: an immunohistochemical double labeling study.
Takeuchi H; Kubota T; Kitai R; Nakagawa T; Hashimoto N
Neuropathology; 2008 Apr; 28(2):127-31. PubMed ID: 18021193
[TBL] [Abstract][Full Text] [Related]
16. Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo.
Said HM; Stein S; Hagemann C; Polat B; Staab A; Anacker J; Schoemig B; Theobald M; Flentje M; Vordermark D
Oncol Rep; 2009 Jan; 21(1):237-46. PubMed ID: 19082468
[TBL] [Abstract][Full Text] [Related]
17. Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells.
Gramatzki D; Pantazis G; Schittenhelm J; Tabatabai G; Köhle C; Wick W; Schwarz M; Weller M; Tritschler I
Oncogene; 2009 Jul; 28(28):2593-605. PubMed ID: 19465936
[TBL] [Abstract][Full Text] [Related]
18. Revisiting the role of p53 in primary and secondary glioblastomas.
Nagpal J; Jamoona A; Gulati ND; Mohan A; Braun A; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2006; 26(6C):4633-9. PubMed ID: 17214319
[TBL] [Abstract][Full Text] [Related]
19. Fibrin deposition in primary and metastatic human brain tumours.
Bárdos H; Molnár P; Csécsei G; Adány R
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):536-48. PubMed ID: 8874864
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
